The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples